Synonym: Daunomycin hydrochloride
|Related Categories||A - K, Aminoglycosides, Antibacterial, Antibiotics, Antibiotics A to Z,|
Daunorubicin inhibits DNA and RNA synthesis as sequence specific ds-DNA intercalating agent. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. Daunomycin effectively binds to every 3 base pairs which causes unwinding.
Potent anticancer agent. Inhibits DNA and RNA synthesis as sequence specific ds-DNA intercalating agent. Properties
Daunorubicin hydrochloride is used in photostability 1, antileukemic, 2, and drug metabolism studies 3.
Customers Also Viewed
|Precautionary statements||P261-P281-P301 + P310-P342 + P311|
|Personal Protective Equipment||Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges|
|Hazard Codes (Europe)||Xn|
|Risk Statements (Europe)||22-40-42/43|
|Safety Statements (Europe)||22-36/37-45|
|RIDADR||UN 2811 6.1 / PGIII|
1. Photoprotection of Daunorubicin Hydrochloride with Sodium Sulfite. Mohammad S. Islam* and Ahmed F. Asker J. Pharm. Sci. 49, 122-126, (1995)
3. Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin. Onkar S. Bains, Thomas A. Grigliatti, et al. J. Pharmacol. Exp. Ther. 335, 533-545, (2010)
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Creutzig U, Zimmermann M, Bourquin JP, et al. Blood 122(1), 37-43, (2013)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Petersdorf SH, Kopecky KJ, Slovak M, et al. Blood 121(24), 4854-60, (2013)
Artesunate has its enhancement on antibacterial activity of β-lactams via increasing the antibiotic accumulation within methicillin-resistant Staphylococcus aureus (MRSA). Jiang W, Li B, Zheng X, et al. J. Antibiot. 66(6), 339-45, (2013)
Probing the relative orientation of molecules bound to DNA through controlled interference using second-harmonic generation. Doughty B, Rao Y, Kazer SW, et al. Proc. Natl. Acad. Sci. U. S. A. 110(15), 5756-8, (2013)
2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein. Jabeen I, Wetwitayaklung P, Chiba P, et al. J. Comput. Aided Mol. Des. 27(2), 161-71, (2013)
Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system. Chhablani J, Nieto A, Hou H, et al. Invest. Ophthalmol. Vis. Sci. 54(2), 1268-79, (2013)
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Kaspers GJ, Zimmermann M, Reinhardt D, et al. J. Clin. Oncol. 31(5), 599-607, (2013)
S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity. Hartmanová T, Tambor V, Lenčo J, et al. Chem. Biol. Interact. 202(1-3), 136-45, (2013)
The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. Xiang L, Li M, Liu Y, et al. Ann. Hematol. 92(8), 1063-9, (2013)
Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Kavcic M, Fisher BT, Li Y, et al. Cancer 119(10), 1916-23, (2013)
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Bertoli S, Bérard E, Huguet F, et al. Blood 121(14), 2618-26, (2013)
High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Hassanein M, Atenafu EG, Schuh AC, et al. Leuk. Res. 37(5), 556-60, (2013)
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study. Krug U, Koschmieder A, Schwammbach D, et al. PLoS ONE 7(12), e52695, (2012)
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Marshall GM, Dalla Pozza L, Sutton R, et al. Leukemia 27(7), 1497-503, (2013)
R.J. White et al. Drugs Pharm. Sci. 22, 569, (1984)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?